Nothing Special   »   [go: up one dir, main page]

DK3260118T3 - Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion - Google Patents

Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion Download PDF

Info

Publication number
DK3260118T3
DK3260118T3 DK17167125.8T DK17167125T DK3260118T3 DK 3260118 T3 DK3260118 T3 DK 3260118T3 DK 17167125 T DK17167125 T DK 17167125T DK 3260118 T3 DK3260118 T3 DK 3260118T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
cognitive function
improving cognitive
improving
Prior art date
Application number
DK17167125.8T
Other languages
English (en)
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3260118T3 publication Critical patent/DK3260118T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17167125.8T 2008-10-16 2009-10-16 Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion DK3260118T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US15263109P 2009-02-13 2009-02-13
US17553609P 2009-05-05 2009-05-05
EP09748527.0A EP2346500B1 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Publications (1)

Publication Number Publication Date
DK3260118T3 true DK3260118T3 (da) 2021-04-19

Family

ID=41403972

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09748527.0T DK2346500T3 (da) 2008-10-16 2009-10-16 Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
DK17167125.8T DK3260118T3 (da) 2008-10-16 2009-10-16 Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09748527.0T DK2346500T3 (da) 2008-10-16 2009-10-16 Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion

Country Status (12)

Country Link
US (5) US20100099735A1 (da)
EP (2) EP3260118B1 (da)
JP (3) JP5917148B2 (da)
CN (2) CN102227217A (da)
AU (1) AU2009303834B2 (da)
BR (1) BRPI0920342A2 (da)
CA (1) CA2740610C (da)
DK (2) DK2346500T3 (da)
EA (1) EA033130B1 (da)
ES (2) ES2637497T3 (da)
HK (2) HK1245099A1 (da)
WO (1) WO2010044878A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2637497T3 (es) 2008-10-16 2017-10-13 The Johns Hopkins University Procedimientos y composiciones para la mejora de la función cognitiva
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US20160030391A1 (en) * 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
MA50634A (fr) * 2015-05-22 2021-04-28 Agenebio Inc Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
EP3458049A1 (en) * 2016-05-20 2019-03-27 Institut Pasteur Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
WO2021063414A1 (zh) * 2019-09-30 2021-04-08 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
BR112023000423A2 (pt) * 2020-07-10 2023-03-14 Agenebio Inc Combinações de agonistas gabaa alfa 5 e inibidores de sv2a e métodos de uso no tratamento de comprometimento cognitivo
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
ATE27T1 (de) * 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) * 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
EP0300111B1 (en) 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
CA2007732A1 (en) 1989-01-17 1990-07-17 Gary L. Olson Cyclohexaneacetamide derivatives
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) * 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) * 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
TWI238062B (en) 1999-12-01 2005-08-21 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
EP1435944B1 (en) 2001-10-16 2009-09-30 Memory Pharmaceutical Corporation 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7465549B2 (en) * 2002-12-03 2008-12-16 Ucb, S.A. Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
KR20060110349A (ko) 2003-12-02 2006-10-24 유씨비 소시에떼아노님 이미다졸 유도체, 이들의 제조 방법 및 이들의 용도
JP2007533741A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤
EP1758855B1 (en) 2004-06-11 2007-11-21 UCB Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
DE05815688T1 (de) * 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
JP2008534522A (ja) * 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
JP2009518333A (ja) 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム キサンチン誘導体、その調製方法及びその使用
WO2007104035A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
EP2152262A2 (en) 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
ES2637497T3 (es) 2008-10-16 2017-10-13 The Johns Hopkins University Procedimientos y composiciones para la mejora de la función cognitiva
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
DK2358360T3 (da) 2008-11-18 2016-12-12 Ucb Biopharma Sprl Forlænget frigivelses-formuleringer omfattende et 2-oxo-1-pyrrolidin derivat
CN104906085A (zh) 2009-01-29 2015-09-16 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物
WO2010089372A1 (en) 2009-02-09 2010-08-12 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function

Also Published As

Publication number Publication date
WO2010044878A1 (en) 2010-04-22
JP2012505883A (ja) 2012-03-08
AU2009303834A1 (en) 2010-04-22
DK2346500T3 (da) 2017-07-17
US8604075B2 (en) 2013-12-10
ES2865504T3 (es) 2021-10-15
EP3260118B1 (en) 2021-03-24
HK1245099A1 (zh) 2018-08-24
EA201170571A1 (ru) 2011-12-30
CA2740610A1 (en) 2010-04-22
JP2016147915A (ja) 2016-08-18
HK1248543A1 (zh) 2018-10-19
US20220218665A1 (en) 2022-07-14
EP2346500A1 (en) 2011-07-27
AU2009303834B2 (en) 2016-08-11
US20240293363A1 (en) 2024-09-05
EA033130B1 (ru) 2019-08-30
EP3260118A1 (en) 2017-12-27
US20100099735A1 (en) 2010-04-22
ES2637497T3 (es) 2017-10-13
US20150094352A1 (en) 2015-04-02
JP6271641B2 (ja) 2018-01-31
CA2740610C (en) 2020-01-07
CN102227217A (zh) 2011-10-26
CN107243007A (zh) 2017-10-13
JP2014169339A (ja) 2014-09-18
JP5917148B2 (ja) 2016-05-11
BRPI0920342A2 (pt) 2020-06-23
US20120046336A1 (en) 2012-02-23
EP2346500B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
DK3260118T3 (da) Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK3663411T3 (da) Fremgangsmåder til digital pcr
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK3272879T3 (da) Transposonendesammensætninger og fremgangsmåder til modificering af nukleinsyrer
DK2247582T3 (da) Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK3006459T3 (da) Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
BRPI0922084A2 (pt) Composições e métodos compreendendo variantes de serina protease
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
DK3133169T3 (da) Fremgangsmåder til selektion og amplificering af polynukleotider
BRPI0910872A2 (pt) equipamento de ostomia temporária
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
BRPI0912046A2 (pt) composições de hibridização e métodos
BRPI1013588A2 (pt) composição
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2446246T3 (da) Indretning og fremgangsmåde til udvælgelse af partikler
BRPI0816494A2 (pt) Composição vedante melhorada
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä